Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zavicefta vs BAT in carbapenem-resistant gram-negative infections (China)
CTR20210953Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- May 2021
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ceftazidime + avibactam in hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), complicated urinary tract infection (cUTI), Intra-abdominal infection (IAI), bloodstream infection (BSI), sponsored by AstraZeneca. Started May 2021; status: completed.
02
Drugs
ceftazidime + avibactam
03
Conditions
hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)complicated urinary tract infection (cUTI)Intra-abdominal infection (IAI)bloodstream infection (BSI)
Beyond the preview
Go deeper on CTR20210953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210953.